Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform
MILWAUKEE (June 30, 2026) — Estrigenix Therapeutics, Inc., together with the University of Wisconsin–Milwaukee Research Foundation, Inc. (UWMRF), Marquette University, and CU Ventures, Inc., today announced the execution of an exclusive license agreement supporting the development of a novel therapeutic platform designed to address the mental and physical effects of menopause. Under the terms of the … Estrigenix Therapeutics Secures Exclusive License Agreement for Novel Menopause Therapeutics Platform